Mrpl13, a mitochondrial ribosomal protein, is an essential component for the structural and functional integrity of the mitoribosome complex, responsible for synthesizing mitochondrial proteins in cells [5,7]. It may be involved in pathways like cell cycle, p53 signaling, PI3K/AKT/mTOR signaling, and Notch signaling pathway, and is of great biological importance in cellular and organismal viability [4,6,7].

In breast cancer, high Mrpl13 expression is associated with worse overall survival, metastasis, and cell invasion, and knockdown of Mrpl13 restrains cell proliferation, migration, and the EMT process through inhibiting the PI3K/AKT/mTOR signaling pathway [1,2,4]. In non-small cell lung cancer, high Mrpl13 level is correlated with poor T classification and overall survival, and its knockdown inhibits cell proliferation [3]. In gastric cancer, high Mrpl13 expression promotes cell cycle progression and proliferation by inhibiting p53 signaling, affecting long-term prognosis [6].

In conclusion, Mrpl13 plays a significant role in promoting cancer cell proliferation, migration, and cell cycle progression in multiple cancer types, including breast, non-small cell lung, and gastric cancers. Studies on Mrpl13 knockout or knockdown in cancer cell models have revealed its importance in cancer-related biological processes, suggesting it could be a potential biomarker and therapeutic target for these diseases.